These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10678786)

  • 1. Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation.
    Garvey M
    Pathogens; 2024 May; 13(6):. PubMed ID: 38921759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.
    Sancar AA; Yegenoglu S; de Vries R; Postma MJ; Simsek N; Pechlivanoglou P; Unal S
    Pharm World Sci; 2008 Dec; 30(6):916-23. PubMed ID: 18803030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staphylococcal skin infections in children: rational drug therapy recommendations.
    Ladhani S; Garbash M
    Paediatr Drugs; 2005; 7(2):77-102. PubMed ID: 15871629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.
    Saleh-Mghir A; Ameur N; Muller-Serieys C; Ismael F; Lemaitre F; Massias L; Feger C; Bléton R; Crémieux AC
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1122-4. PubMed ID: 11897604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
    Klastersky J
    Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
    Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for gram-positive nosocomial sepsis.
    Wood MJ
    J Chemother; 1999 Dec; 11(6):446-52. PubMed ID: 10678786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.